欧州連合 - 英語 - EMA (European Medicines Agency)

merck europe b.v.  - follitropin alfa, lutropin alfa - infertility, female - sex hormones and modulators of the genital system, - pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (lh) and follicle-stimulating-hormone deficiency.in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

欧州連合 - 英語 - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - follitropin delta - anovulation - sex hormones and modulators of the genital system, - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

欧州連合 - 英語 - EMA (European Medicines Agency)

n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - sex hormones and modulators of the genital system, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - deslorelin as deslorelin acetate - parenteral implant, device - deslorelin as deslorelin acetate ungrouped active 9.4 mg/im - endocrine system - dog - male - reducing testosterone production

カナダ - 英語 - Health Canada

abbvie corporation - elagolix (elagolix sodium) - tablet - 150mg - elagolix (elagolix sodium) 150mg - gonadotropin-releasing hormone antagonists

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - deslorelin as deslorelin acetate - parenteral implant, device - deslorelin as deslorelin acetate ungrouped active 4.7 mg/im - endocrine system - dog - male - reducing testosterone production

イスラエル - 英語 - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as embonate - powder and solvent for suspension for injection - triptorelin as embonate 22.5 mg - triptorelin - symptomatic treatment of advanced hormone-dependent prostate cancer. as an alternative treatment, if orchiectomy or the administration of oestrogens are not indicated or are unacceptable to the patient. treatment of central precocious puberty (cpp) in children 2 years and older with an onset of cpp before 8 years in girls and 10 years in boys.

イスラエル - 英語 - Ministry of Health

j-c health care ltd - apalutamide - film coated tablets - apalutamide 60 mg - apalutamide - "erleada is indicated in adult men for the treatment of• metastatic hormone‐sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt)• non-metastatic castration-resistant prostate cancer (nm-crpc)."